Skip to Main Content
Try STAT+ TODAY
Trending:
Coronavirus
First Opinion
Health
Biotech
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Politics
STAT+

Two Silicon Valley insiders meet with Trump about heading FDA

By Sheila Kaplan and Ike Swetlitz Jan. 12, 2017

Reprints
FDA; Drug Administration campus
Andrew Harnik/AP

Two critics of the Food and Drug Administration met with President-elect Donald Trump Thursday to discuss running the agency.

Silicon Valley insiders Jim O’Neill and Balaji Srinivasan have both called for major agency overhauls.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Authors Reprints

Sheila Kaplan

Senior Writer, Washington

Sheila Kaplan is a senior writer for STAT, covering the intersection of science, money, and politics.

Ike Swetlitz

Washington Correspondent

Ike is a Washington correspondent, reporting at the intersection of life science and national politics.

Tags

Trending
CDC_MONKEYPOX
EU health agency warns monkeypox could become endemic in…
EU health agency warns monkeypox could become endemic in Europe if outbreak continues
U.S. reports 180 cases of unexplained hepatitis in children,…
U.S. reports 180 cases of unexplained hepatitis in children, as researchers investigate potential causes
Monkeypox
A CDC expert answers questions on monkeypox
A CDC expert answers questions on monkeypox
Recommended
AstraZeneca building
AstraZeneca’s ambitious vaccine dreams are finally, officially dead
AstraZeneca’s ambitious vaccine dreams are finally, officially dead
Cambridge: AbbVie
AbbVie dramatically boosts its spending on lobbying
AbbVie dramatically boosts its spending on lobbying
GNC supplements vitamins
As Congress takes up FDA oversight of dietary supplements,…
As Congress takes up FDA oversight of dietary supplements, a lobbying showdown looms

Recommended Stories

OrigamiBoats_Illustration_MollyFerguson_051822
A STAT Investigation

How a complex web of businesses turned private health records from GE into a lucrative portrait of patients

By Casey Ross

pills
Pharmalot

European regulator suspends generic drugs after finding flawed studies

By Ed Silverman

Blue inhaler
Pharmalot

Drugmakers use monopoly tactics to thwart lower-cost generic competition for inhalers, analysis finds

By Ed Silverman

Pills dollar QALY
Pharmalot

Two dozen states side with HHS in its raucous dispute with pharma over a drug discount program

By Ed Silverman

BiotechClawMachine_Illustration_MollyFerguson_051122
Biotech

When biotech acquisitions spike, early-stage startups are prime targets, analysis shows

By Kate Sheridan